Pharmaceutical Technology Europe, Feb 1, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology Europe, Feb 1, 2012
Editor's Comment
Cliffhanger
By Rich Whitworth
"The patent expiry of several major blockbuster drugs worth $150 billion between 2010 and 2017 will fuel the growth of the global generic pharmaceuticals market," so says a press release announcing new analysis from Frost & Sullivan.
Special Feature
Pointed Debate: Expert Views on Injectables
By Dr Charles Potter , Steven Kaufman , Mark Novara , Peter Sadowski
We bring industry experts together to discuss the importance of self-administration and what injection technologies are best suited to this cause.
Peer-Reviewed Research
Evaluating Impurities in Drugs (Part I of III)
In Part I of a three-part article, the authors discuss what constitutes an impurity and the potential sources of impurities in APIs and finished drug products.
Industry Insider
2012: A Good, Bad or Ugly Year for Servier?
By Nathan Jessop
The scandal surrounding Servier's diabetes drug, Mediator, continues to unravel in France and could have implications for the whole pharmaceutical industry as the country scrutinises its regulatory systems.
Ask the Expert
Head in the Clouds
By Subhro Mallik
We interview Subhro Mallik from IT firm Infosys about how pharma is responding to the cloud computing phenomenon and what more can be done to realise business benefits.
Disposables Advisor
Understanding Gamma Sterilisation
By Jerold Martin
This column will address some of the questions on how single use systems are sterilized by gamma irradiation and what documentation may be requested by regulators.
Interview
Decoding the Hype and Fear of Nanomedicines
By Ruth Duncan
Does nanotechnology offer a cure-all or a kill all? We speak with Ruth Duncan about the real potential of nanomedicines.
News
News: FDA's Social Media Insight
By Stephanie Sutton
How can pharma make use of social media opportunities without running afoul of regulators?

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Click here